GPR143: A Potential Drug Target for Albinism (G4935)

GPR143: A Potential Drug Target for Albinism

GPR143 is a G protein-coupled receptor (GPCR) that is expressed in the retina and is involved in the sense of light and vision. Albinism, also known as blindness or partial blindness, is a group of genetic disorders that result in the loss of vision. GPR143 has been identified as a potential drug target or biomarker for the treatment of albinism.

The GPCR is a transmembrane protein that plays a critical role in cellular signaling. It is composed of an extracellular portion and an intracellular portion that contains a catalytic domain and a regulatory domain. The extracellular portion of GPCR is involved in cell-cell signaling, while the intracellular portion contains the regulatory domain that interacts with intracellular signaling molecules.

GPR143 is a member of the GPCR family and is expressed in the retina, where it is involved in the sense of light and vision. The retina is a sensitive organ that is responsible for detecting light and transmitting signals to the brain, which allows us to see the world around us. GPR143 is involved in the development and maintenance of normal retinal function, including the formation of photoreceptor cells and the transmission of signals from the retina to the brain.

In addition to its role in vision, GPR143 is also involved in the regulation of pain and inflammation. It is a potent modulator of pain perception and can inhibit the activity of pain-sensitive neurons. GPR143 has also been shown to be involved in the regulation of inflammation, including the production of pro-inflammatory cytokines.

As a potential drug target, GPR143 is an attractive target for the treatment of albinism because of its involvement in the sense of light and vision. Albinism is a group of genetic disorders that results in the loss of vision. The most common form of albinism is autosomal recessive albinism, which is caused by the loss of a single gene. The loss of GPR143 gene leads to the development of autosomal recessive albinism.

GPR143 has been shown to be involved in the development and maintenance of normal retinal function, including the formation of photoreceptor cells and the transmission of signals from the retina to the brain. It is also involved in the regulation of pain and inflammation. As a potential drug target, GPR143 can be targeted with small molecules or antibodies to treat the symptoms of autosomal recessive albinism.

In addition to its potential as a drug target, GPR143 is also a potential biomarker for the diagnosis of albinism. The loss of GPR143 gene leads to the development of autosomal recessive albinism, which is characterized by the loss of vision and the formation of white blood cells with lower than normal levels of a protein called melanin. Therefore, measuring the level of melanin in blood or urine samples can be used as a biomarker for the diagnosis of albinism.

GPR143 is also a potential target for the development of new therapies for other genetic disorders that result in the loss of vision, such as age-related macular degeneration (AMD) and optic neuritis. AMD is a progressive disease that affects the macula, a part of the retina responsible for our central vision, and is the leading cause of blindness in the developed world. GPR143 has been shown to be involved in the development and maintenance of normal retinal function, including the formation of photoreceptor cells and the transmission of signals from the retina to the brain. This suggests that GPR143 may be a useful target for the development of new therapies for AMD.

In conclusion, GPR143 is a GPCR that is expressed in the retina and is involved in the sense of light and vision. The loss of GPR143 gene leads to the development of autosomal recessive albinism, which is characterized by the loss of vision and the formation of white blood cells with lower than normal levels of melanin. GPR143 is also involved in the regulation of pain and inflammation and can be a potential drug target or biomarker for the treatment of albinism. Additionally, GPR143 may be a useful target for the development of new therapies for other genetic disorders that result in the loss of vision. Further research is needed to fully understand the role of GPR143 in the treatment of albinism and to develop new therapies that can help to treat this genetic disorder.

Protein Name: G Protein-coupled Receptor 143

Functions: Receptor for tyrosine, L-DOPA and dopamine. After binding to L-DOPA, stimulates Ca(2+) influx into the cytoplasm, increases secretion of the neurotrophic factor SERPINF1 and relocalizes beta arrestin at the plasma membrane; this ligand-dependent signaling occurs through a G(q)-mediated pathway in melanocytic cells. Its activity is mediated by G proteins which activate the phosphoinositide signaling pathway. Also plays a role as an intracellular G protein-coupled receptor involved in melanosome biogenesis, organization and transport

More Common Targets

GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17 | GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1 | GPRIN2 | GPRIN3 | GPS, PLAT and transmembrane domain-containing protein | GPS1 | GPS2 | GPS2P1 | GPSM1 | GPSM2 | GPSM3 | GPT | GPT2 | GPX1 | GPX1P1 | GPX2 | GPX3 | GPX4 | GPX5 | GPX6 | GPX7 | GPX8